Sinopharm, a Chinese state-run pharmaceutical company, announced on Monday that it had submitted an application for clinical trials of an “Omicron-specific mRNA COVID-19 [Chinese coronavirus] vaccine [candidate]” that it allegedly produced, China’s state-run Global Times reported.